title: Sildenafil citrate therapy for severe early-onset intrauterine growth restriction.
abstract: Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011;118:624-628. Currently, there is no effective therapy for severe early-onset intrauterine growth restriction (IUGR). Sildenafil citrate vasodilates the myometrial arteries isolated from women with IUGR-complicated pregnancies. Women were offered Sildenafil (25 mg three times daily until delivery) if their pregnancy was complicated by early-onset IUGR [abdominal circumference (AC)< 5th percentile] and either the gestational age was <25(+0) weeks or an estimate of the fetal weight was <600 g (excluding known fetal anomaly/syndrome and/or planned termination). Sildenafil treatment was associated with increased fetal AC growth [odds ratio, 12.9; 95% confidence interval (CI), 1.3, 126; compared with institutional Sildenafil-naive early-onset IUGR controls]. Randomised controlled trial data are required to determine whether Sildenafil improves perinatal outcomes for early-onset IUGR-complicated pregnancies.
authors.affiliation: Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada. pvd@cw.bc.ca
authors.forename: P
authors.initials: P
authors.lastname: von Dadelszen
authors.forename: S
authors.initials: S
authors.lastname: Dwinnell
authors.forename: L A
authors.initials: LA
authors.lastname: Magee
authors.forename: B C
authors.initials: BC
authors.lastname: Carleton
authors.forename: A
authors.initials: A
authors.lastname: Gruslin
authors.forename: B
authors.initials: B
authors.lastname: Lee
authors.forename: K I
authors.initials: KI
authors.lastname: Lim
authors.forename: R M
authors.initials: RM
authors.lastname: Liston
authors.forename: S P
authors.initials: SP
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Rurak
authors.forename: R L
authors.initials: RL
authors.lastname: Sherlock
authors.forename: M A
authors.initials: MA
authors.lastname: Skoll
authors.forename: M M
authors.initials: MM
authors.lastname: Wareing
authors.forename: P N
authors.initials: PN
authors.lastname: Baker
mesh_terms: D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D016022:Case-Control Studies; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D054238:Perinatal Mortality; D010879:Piperazines / Q000627:therapeutic use*; D010920:Placenta / Q000098:blood supply; D011247:Pregnancy; D011256:Pregnancy Outcome; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D014599:Uterus / Q000098:blood supply; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate